GLP-1 single agonist vs. GLP-1/GIP dual agonist: Why does telopoietin have greater weight loss potential?

Currently, GLP-1 receptor agonists have become mainstream drugs in the treatment of weight loss and diabetes . Among them, monoagonal agonists (such as semaglutide, brand name: Vigovite) and dual agonists (such as telpolide) are the two most watched classes of drugs.

GLP-1 monoagonals primarily control weight by reducing appetite and delaying gastric emptying , while GLP-1/GIP dual agonists, on the other hand, add the ability to promote fat metabolism , resulting in stronger weight loss and more stable long-term weight management.

So why does telpolide, with its dual-agonist mechanism, deliver a stronger weight loss effect? ​​This article will provide a detailed analysis from four aspects: mechanism of action, clinical research data, side effects, and long-term weight maintenance capabilities .

 

1. GLP-1 vs. GLP-1/GIP : Comparison of Mechanisms of Action

Mechanism of action	GLP-1 monoagonal agent (semaglutide)	GLP-1/GIP dual agonist (Telborpeptide)
Reduce appetite	powerful	powerful
Delaying gastric emptying	powerful	powerful
Promote fat metabolism	No direct effect	Strong ( GIP effect)
Improve insulin sensitivity	Moderate	Stronger ( GIP effect)
Reduce gastrointestinal side effects	none	Stronger ( GIP can reduce nausea and other discomfort)

📌 Key differences :

1. GLP-1 monoagonal agonists (such as smegglutide) primarily act on the appetite center in the brain , reducing food intake and slowing gastric emptying , making it easier for people to reduce calorie intake.
2. GLP-1/GIP dual agonists (such as telpolide) work on the basis of GLP-1 action, and promote fat breakdown and improve insulin sensitivity through GIP , resulting in greater weight loss and more comprehensive metabolic improvement .
3. The GIP effect of telpolide can also reduce GLP-1 -related nausea and discomfort and improve long-term tolerance .

in conclusion :

•       GLP-1 monoagonals primarily rely on reducing appetite and delaying gastric emptying, while GLP-1/GIP dual agonists additionally enhance fat metabolism, thus making telpoide more effective for weight loss.

 

2. Comparison of clinical research data: Which method is more effective for weight loss?

Research	GLP-1 monoagonal agent (semaglutide)	GLP-1/GIP dual agonist (Telborpeptide)
STEP-1 study (semaglutide)	Weight loss of 16.9% after 68 weeks	-
SURMOUNT-1 study (Telborpeptide)	-	Weight loss of 22.5% after 72 weeks
Proportion of patients with a weight loss of ≥20%	36%	57%

📌 Data Analysis :

•       In the STEP-1 study (smegglutide), patients using the highest dose experienced a 16.9% weight loss , with 36% of subjects experiencing a weight loss of more than 20% .

•       In the SURMOUNT-1 study (telborpeptide), patients using the highest dose experienced a 22.5% weight loss , with 57% of subjects experiencing a weight loss of more than 20% .

•       The weight loss effect of telpotetide is 5.6% higher than that of smegglutide , and a higher proportion of patients achieve their weight loss target of more than 20% .

📌 Why is telpoeptide more effective for weight loss?

•       GLP-1 reduces appetite, while GIP accelerates fat metabolism . This dual mechanism allows the body to burn fat more efficiently, rather than simply reducing calorie intake.

•       GIP can also improve insulin sensitivity, reduce insulin resistance, and further optimize metabolism .

in conclusion :

•       If the goal is to minimize weight loss, a dual GLP-1/GIP agonist (telborpeptide) is more effective than a single agonist (semaglutide).

 

3. Side effects comparison: Which is better tolerated?

Side effect categories	GLP-1 monoagonal agent (semaglutide)	GLP-1/GIP dual agonist (Telborpeptide)
Nausea and vomiting	High ( 44% experienced nausea, 24% experienced vomiting)	Low ( 31% experienced nausea, 18% experienced vomiting)
Diarrhea / Constipation	Possible	It may happen, but it will be mild.
Hypoglycemia (in non-diabetic individuals)	Low	Low
Weight rebound after stopping medication	Faster	Slower

📌 Side effect analysis :

•       The main side effects of GLP-1 drugs are gastrointestinal discomfort (such as nausea, vomiting, and diarrhea), but the GIP action of telpolide can reduce these side effects , thus making it more tolerable .

•       GLP-1 monoagonal drugs (such as semaglutide) cause rapid weight rebound after discontinuation, while telpotetide has a more stable weight maintenance effect .

in conclusion :

•       If you have been unable to continue using semaglutide due to side effects (such as nausea and vomiting), telpolide may be a better alternative.

 

4. Conclusion: Why does telpolide have greater weight loss potential?

1. The mechanism of action of GLP-1/GIP dual agonists is stronger :

•       GLP-1 function : Reduces appetite and slows gastric emptying.

•       GIP's effects : accelerates fat burning, improves insulin sensitivity, and reduces gastrointestinal discomfort.

2. Clinical research data shows that telpolide has a stronger weight loss effect :

•       After 72 weeks, the average weight loss was 22.5% , which is higher than that of smegglutinin ( 16.9% ).

•       More than 57% of patients experienced a weight loss of over 20% , compared to only 36% for smegglutinin.

3. Fewer side effects and higher tolerability :

•       GIP can reduce nausea and vomiting, and improve adherence to long-term use .

•       Weight is maintained more stably, and the risk of rebound after stopping medication is lower .

📌 Final recommendation :
✔ If you want to achieve maximum weight loss, telpoeptide is a better choice.
✔ If you have difficulty tolerating the side effects of smegglutide, telpolide may be a milder alternative.